Explore Travere Therapeutics' Q4 2024 Financial Report highlighting $233M in revenue and increased net losses. Insights and hold recommendation for investors.
Explore the latest 8-K filing from Travere Therapeutics (TVTX) detailing vital financials and updates as of February 20, 2025. Essential for stakeholders and investors.
Explore key details from Travere Therapeutics, Inc.'s 8-K SEC filing on February 11, 2025, including stock info and company registration.
Discover essential insights from Travere Therapeutics' 8-K report filed on January 13, 2025. Stay updated on significant corporate changes impacting TVTX stock.